Sajeet Sawhney, MD
Nephrology · Fountain Valley, CANPI 1003131228
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 154 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,474 and has fallen 87.8% since, to $179 in 2025.
Across 154 payments — averaging $23.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$820
- Amgen$459
- Akebia Therapeutics Inc$373
- Otsuka America Pharmaceutical, Inc.$252
- Fresenius USA Marketing, Inc.$235
- AstraZeneca$175
- plus $1K from 17 others
Across 2 payments — averaging $289.81 each. An ownership or investment interest held by the physician or an immediate family member.
- Exthera Medical Corporation$580
What the payments were for
- Food & beverage$3,49796%
- Education$1294%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 31 | $820 |
| Amgen(2 entities) | 23 | $459 |
| Akebia Therapeutics Inc | 22 | $373 |
| Otsuka America Pharmaceutical, Inc. | 12 | $252 |
| Fresenius USA Marketing, Inc. | 15 | $235 |
| AstraZeneca(2 entities) | 8 | $175 |
| Bayer | 8 | $171 |
| OPKO Pharmaceuticals, LLC | 8 | $169 |
| Aurinia Pharma U.S., Inc. | 8 | $162 |
| Bard Peripheral Vascular, Inc. | 1 | $159 |
| Mallinckrodt Hospital Products Inc. | 3 | $142 |
| Veloxis Pharmaceuticals, Inc. | 1 | $124 |
| Calliditas Therapeutics US Inc. | 3 | $75 |
| Baxter Healthcare | 1 | $72 |
| Nxstage Medical, Inc. | 1 | $43 |
| GSK | 2 | $40 |
| Lilly USA, LLC | 1 | $34 |
| Sanofi | 1 | $25 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $19 |
| Johnson & Johnson | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,626 in reported general payments places this provider in the 70th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 75 | $197,027 |
| JardianceEmpagliflozin | 118 | $148,678 |
| FarxigaDapagliflozin Propanediol | 113 | $117,130 |
| ProcritEpoetin Alfa | 48 | $99,086 |
| VeltassaPatiromer Calcium Sorbitex | 64 | $66,125 |
| XphozahTenapanor Hcl | 13 | $42,769 |
| TradjentaLinagliptin | 30 | $33,154 |
| Sevelamer Carbonate | 122 | $32,818 |
| JanuviaSitagliptin Phosphate | 27 | $29,650 |
| LokelmaSodium Zirconium Cyclosilicate | 31 | $23,856 |
| AuryxiaFerric Citrate | 16 | $22,444 |
| RetacritEpoetin Alfa-Epbx | 25 | $11,922 |
| Calcium Acetate | 58 | $5,816 |
| NeoralCyclosporine, Modified | 12 | $5,688 |
| ProsolParenteral Amino Acid 20% No.1 | 16 | $3,621 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $235 | $197,02775 claims |
| Boehringer IngelheimJardiance, Tradjenta | $19 | $181,833148 claims |
| AstraZenecaFarxiga, Lokelma | $175 | $140,986144 claims |
| Johnson & JohnsonProcrit | $17 | $99,08648 claims |
| Akebia Therapeutics IncAuryxia | $373 | $22,44416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,341 nephrology providers in California.
Other nephrology in Fountain Valley
- Ajit SawhneyFountain Valley$89K
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.